Repligen (RGEN) Stock Forecast & Price Target

Repligen is benefiting from a broad bioprocessing recovery, with Q3 showing strong overall results, capital equipment orders up mid-teens year over year to a five-year high, and consumables growth near 20% led by Chromatography at +50% and Proteins at +40%. Its core franchises remain well positioned: filtration is still the largest segment at about 55% of revenue, but improving order trends, sustained China momentum above 40%, and healthy demand in North America and EMEA support a durable mid-teens organic growth profile. Guidance for FY26 also reinforces the outlook, with organic growth narrowed to 12%-13% and adjusted operating income raised to $135 million-$139 million, while the BioLife contribution and a near-lapping of new-modality headwinds should further strengthen growth and profitability.

Repligen is vulnerable to a sluggish recovery in equipment demand if the hoped-for reshoring boost never becomes actual purchase orders, leaving a key driver of growth unsupported. Its outlook is further pressured by competitive threats to ATF products, which account for nearly 20% of sales, and by concentration in higher-risk modalities such as cell and gene therapy and mRNA that could face broader customer setbacks. Additional downside comes from premium valuation risk, while regulatory uncertainty, larger competitors, limited acquisition opportunities, and liquidity issues may amplify multiple compression.